News from shire plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 10, 2018, 18:16 ET Shire Announces The Pricing Terms And Increase In The Maximum Tender Amount Of The Previously Announced Cash Tender Offers For Certain Outstanding Notes

Shire plc (LSE: SHP and NASDAQ: SHPG) ("Shire"), Baxalta Incorporated, a Delaware corporation and wholly-owned subsidiary of Shire ("Baxalta"), and...


Sep 10, 2018, 08:47 ET Shire Announces Early Results Of The Previously Announced Cash Tender Offers For Certain Outstanding Notes

Shire plc (LSE: SHP and NASDAQ: SHPG) ("Shire"), Baxalta Incorporated, a Delaware corporation and wholly-owned subsidiary of Shire ("Baxalta"), and...


Aug 24, 2018, 08:32 ET Shire Announces Cash Tender Offers for up to $2,250,000,000 Outstanding Principal Amount of Notes

Shire plc (LSE: SHP and NASDAQ: SHPG) ("Shire"), Baxalta Incorporated, a Delaware corporation and wholly-owned subsidiary of Shire ("Baxalta"), and...


May 15, 2018, 07:00 ET Shire Recognizes MPS Awareness Day 2018 with Digital Campaign and Global Events Focused on Increasing Diseases Awareness

Shire plc (LSE: SHP, NASDAQ: SHPG) announces its third annual #FlyforMPS campaign to allow rare champions around the world to recognize and raise...


Jun 22, 2017, 01:00 ET Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease

VEYVONDI is the first and only recombinant von Willebrand factor treatment for adults with von Willebrand disease, the most common inherited bleeding ...


Jun 20, 2017, 18:48 ET Shire plc: U.S. FDA Approves Mydayis[TM] (Mixed Salts of a Single-Entity Amphetamine Product) - A New Once-Daily Option for ADHD Symptom Control in Patients 13 Years and Older

Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) has approved MYDAYIS[TM] (mixed salts of a...


May 25, 2017, 07:00 ET Shire to Participate at the Jefferies Healthcare Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, MD, Chief Executive Officer, will participate at the Jefferies Healthcare...


May 19, 2017, 01:00 ET Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology

New clinical and real-life data in chronic hypoparathyroidism, to advance understanding of this rare disease and improve patients' lives Shire plc...


May 18, 2017, 09:00 ET The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis

Study met primary endpoint demonstrating significantly greater remission rates in patients receiving anti-MAdCAM antibody (SHP647) compared to...


May 18, 2017, 07:00 ET Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial

Significant reduction in monthly Hereditary Angioedema (HAE) attack rate with infrequent subcutaneous administration Data to serve as basis for U.S....


May 16, 2017, 07:00 ET Shire Continues 20-Year Commitment to ADHD with New Research at 2017 Annual Meeting of American Psychiatric Association

Shire plc (LSE: SHP, NASDAQ: SHPG) will present research on the evolving needs of adults living with Attention-Deficit/Hyperactivity Disorder (ADHD)...


May 02, 2017, 07:00 ET Shire Delivers Strong Q1 2017 Revenue Growth While Advancing Late-stage Pipeline

Commercial execution, efficiency improvements, and debt pay-down remain top priorities Shire plc (Shire) (LSE: SHP, NASDAQ: SHPG) announces unaudited ...


May 01, 2017, 07:00 ET Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications

Demonstrates ongoing commitment to innovation in ophthalmics for Shire P-321 is a Phase 2 investigational topical treatment for dry eye disease Shire ...


Apr 26, 2017, 01:00 ET Shire Granted EU Conditional Marketing Authorisation for Natpar[®▼] (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission (EC) has granted Conditional Marketing Authorisation for Natpar...


Apr 25, 2017, 07:00 ET Shire to Participate at the Deutsche Bank 42nd Annual Health Care Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Jeff Poulton, Chief Financial Officer, will participate at the Deutsche Bank 42nd annual health...


Apr 24, 2017, 01:00 ET Shire Launches #PIPostsThanks Social Campaign to Raise Awareness of Primary Immunodeficiency (PI)

Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, is launching #PIPostsThanks, a social campaign to spotlight the unsung heroes ...


Apr 17, 2017, 01:00 ET Shire plc: Data Show A Bleeding Episode Occurs Every Three to 15 Seconds in People Living With Hemophilia Worldwide

On World Hemophilia Day 2017, Shire challenges the community to collectively improve global standards of care for rare bleeding disorders Shire plc...


Mar 30, 2017, 04:41 ET INTUNIV® (Guanfacine Hydrochloride Prolonged Release), a Non-stimulant for the Treatment of ADHD, Receives Approval in Japan

A New Non-stimulant Clinical Option for Children and Adolescents From 6 to 17 Years old With ADHD Shire plc (LSE: SHP, NASDAQ: SHPG) today announced...


Mar 22, 2017, 07:00 ET Shire Receives FDA Fast Track Designation for Recombinant ADAMTS13 (SHP655) for Treatment of Hereditary Thrombotic Thrombocytopenic Purpura

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for...


Mar 16, 2017, 02:00 ET Shire Receives European Approval for Label Extension of CINRYZE®▼(C1 inhibitor [human]) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE

CINRYZE is now the first and only Hereditary angioedema treatment approved for routine prevention in paediatrics Shire plc (LSE: SHP, NASDAQ: SHPG)...


Mar 06, 2017, 12:55 ET CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative to Patients' Previous Immunoglobulin Therapy

Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases and highly specialized conditions, will present data assessing primary...


Mar 01, 2017, 06:00 ET Shire to Participate at the Cowen 37th Annual Healthcare Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Jeff Poulton, Chief Financial Officer, will participate at the Cowen 37th Annual Healthcare...


Feb 24, 2017, 06:17 ET CHMP Recommends EU Conditional Marketing Authorisation for Natpar® (Parathyroid Hormone) for Patients with Chronic Hypoparathyroidism

This Press Release is intended for Global Use If approved, Natpar would be the first licensed recombinant parathyroid hormone in Europe for the...


Feb 23, 2017, 03:11 ET New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease

Results Served as Basis for Ongoing Phase 3 Trial Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, today announced the...


Feb 23, 2017, 01:00 ET Shire Launches 'Rare Count' Campaign to Personalize the Global Impact of Rare Diseases

- For Every 'Count', Shire Will Donate to Leading Rare Disease Organizations - Campaign Honoring Rare Disease Day Open to All at...